Global Gastritis Treatment Market: Industry Analysis and forecast 2019 – 2027: By Type, Drug Class, End-User,and Region.

Global Gastritis Treatment Market size was valued US$ XX Mn. in 2019 and the total revenue is expected to grow at 4.5% from2019 to 2027, reaching nearly US$ XX Mn. To know about the Research Methodology :- Request Free Sample Report The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis. Gastritis is usually caused by the bacteria helicobacter pylori or by the usage of non-steroidal anti-inflammatory drugs. It can be cured by accurate treatment and henceforth the demand for gastritis treatment will upsurge in the future. The MMR report analyzes factors affecting the gastritis treatment market from both demand and supply side and further estimates market dynamics affecting the market during 2019-2027 i.e., drivers, restraints, challenges, and opportunities. The major players are investing heavily in their R&D activities to come up with altered treatments of the disease. The companies are exploring new layouts through acquisitions and expansions to avail a competitive advantage over combined synergies. The gastritis treatment market is expanding because of advances in medicinal technologies and growing fast-food chains worldwide. As per the National Center for Biotechnology report, there were approximately 98 million new cases of gastritis in 2015. Also, the prevalence of gastritis upsurge with age according to the same report. So, the demand for gastritis treatment will rise at a steady rate over 2019-2027. By type, acute gastritis segment dominated the gastritis treatment market, with a market size of US$ XX Mn in 2019 and to reach US$ XX Mn by 2027, with a CAGR of XX.22%. Acute Gastritis is caused owing to the overuse of NSAID (Non-Steroidal Anti-Inflammatory) drugs such as sodium naproxen, diclofenac, and ibuprofen, with complications like erosion and hemorrhages. It is identified by antacids for example proton pump and famotidine (Pepcid) inhibitors that aids in the suppression of extreme acid production helping towards the gastritis treatment market’s growth. Likewise, the MMR report covers the segments in the gastritis treatment market such as type, drug class, and end-user. North America Gastritis Treatment Market was valued US$ XX Mn.in 2019 and is expected to reach a value of US$ XX Mn. by 2027, with a CAGR of XX.10% during the forecast period. This is attributed to high awareness amongst the patients, and in America, the US is a major stakeholder thanks to the strong players. APAC and Europe are the fastest growing market in the gastritis treatment market because of high incidence. The economic conditions in the APAC region raise the gastritis treatment market to novel heights. The MEA regions and South America are also showing significantly less growth due to less knowledge regarding gastritis treatment during 2019-2027. Major players in the global gastritis treatments market are more focused on improving their service & product offerings through many strategic approaches.Teva Pharmaceuticals Company acquired Allergan’s generics business in 2016. This acquisition aided the company in delivering the highest-quality drugs at the most competitive costs, healthcare systems, unlocking the value to patients, and investors around the globe. The objective of the report is to present a comprehensive analysis of the Global Gastritis Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Gastritis Treatment Market dynamics, structure by analyzing the market segments and projects the Global Gastritis Treatment Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Gastritis Treatment Market make the report investor’s guide.

Scope of the Global Gastritis Treatment Market: Inquire before buying

Global Gastritis Treatment Market, By Type

• Acute Gastritis • Chronic Gastritis • Erosive Gastritis • Non-Erosive Gastritis

Global Gastritis Treatment Market, By Drug Class

• Acid blocking medicines • Antibiotics • Antacids • Acid reducing medicines • Others

Global Gastritis Treatment Market, By End user

• Government • Hospitals • Medical Practitioners • Others

Global Gastritis Treatment Market, By Region

• Asia Pacific  India  China  Japan  South Korea  Australia  Indonesia  Malaysia  Vietnam  Rest of Asia • North America  U.S.  Canada • Europe  U.K  Germany  France  Russia  Spain  Italy  Sweden • South America  Mexico  Brazil  Rest of South America • Middle East & Africa  GCC  South Africa  Rest of MEA

Key players operating in the Global Gastritis Treatment Market

• Pfizer • AstraZeneca • Novartis • Cipla • Teva Pharmaceuticals • Abbott Laboratories • Microbiotix • Reddy's Laboratories • Lupin Ltd • Perrigo Pharmaceutical • Zydus Cadila Healthcare Limited • Sun Pharmaceutical Industries • PT Otsuka Indonesia
Global Gastritis Treatment Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Gastritis Treatment Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Gastritis Treatment Market Analysis and Forecast 6.1. Gastritis Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Gastritis Treatment Market Analysis and Forecast, By Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Gastritis Treatment Market Value Share Analysis, By Drug Class 7.4. Gastritis Treatment Market Size (US$ Mn) Forecast, By Drug Class 7.5. Gastritis Treatment Market Analysis, By Drug Class 7.6. Gastritis Treatment Market Attractiveness Analysis, By Drug Class 8. Global Gastritis Treatment Market Analysis and Forecast, By Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Gastritis Treatment Market Value Share Analysis, By Type 8.4. Gastritis Treatment Market Size (US$ Mn) Forecast, By Type 8.5. Gastritis Treatment Market Analysis, By Type 8.6. Gastritis Treatment Market Attractiveness Analysis, By Type 9. Global Gastritis Treatment Market Analysis and Forecast, By End user 9.1. Introduction and Definition 9.2. Key Findings 9.3. Gastritis Treatment Market Value Share Analysis, By End user 9.4. Gastritis Treatment Market Size (US$ Mn) Forecast, By End user 9.5. Gastritis Treatment Market Analysis, By End user 9.6. Gastritis Treatment Market Attractiveness Analysis, By End user 10. Global Gastritis Treatment Market Analysis, by Region 10.1. Gastritis Treatment Market Value Share Analysis, by Region 10.2. Gastritis Treatment Market Size (US$ Mn) Forecast, by Region 10.3. Gastritis Treatment Market Attractiveness Analysis, by Region 11. North America Gastritis Treatment Market Analysis 11.1. Key Findings 11.2. North America Gastritis Treatment Market Overview 11.3. North America Gastritis Treatment Market Value Share Analysis, By Drug Class 11.4. North America Gastritis Treatment Market Forecast, By Drug Class 11.4.1. Acid blocking medicines 11.4.2. Antibiotics 11.4.3. Antacids 11.4.4. Acid reducing medicines 11.4.5. Others 11.5. North America Gastritis Treatment Market Value Share Analysis, By Type 11.6. North America Gastritis Treatment Market Forecast, By Type 11.6.1. Acute Gastritis 11.6.2. Chronic Gastritis 11.6.3. Erosive Gastritis 11.6.4. Non-Erosive Gastritis 11.7. North America Gastritis Treatment Market Value Share Analysis, By End user 11.8. North America Gastritis Treatment Market Forecast, By End user 11.8.1. Government 11.8.2. Hospitals 11.8.3. Medical Practitioners 11.8.4. Others 11.9. North America Gastritis Treatment Market Value Share Analysis, by Country 11.10. North America Gastritis Treatment Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Gastritis Treatment Market Analysis, by Country 11.12. U.S. Gastritis Treatment Market Forecast, By Drug Class 11.12.1. Acid blocking medicines 11.12.2. Antibiotics 11.12.3. Antacids 11.12.4. Acid reducing medicines 11.12.5. Others 11.13. U.S. Gastritis Treatment Market Forecast, By Type 11.13.1. Acute Gastritis 11.13.2. Chronic Gastritis 11.13.3. Erosive Gastritis 11.13.4. Non-Erosive Gastritis 11.14. U.S. Gastritis Treatment Market Forecast, By End user 11.14.1. Government 11.14.2. Hospitals 11.14.3. Medical Practitioners 11.14.4. Others 11.15. Canada Gastritis Treatment Market Forecast, By Drug Class 11.15.1. Acid blocking medicines 11.15.2. Antibiotics 11.15.3. Antacids 11.15.4. Acid reducing medicines 11.15.5. Others 11.16. Canada Gastritis Treatment Market Forecast, By Type 11.16.1. Acute Gastritis 11.16.2. Chronic Gastritis 11.16.3. Erosive Gastritis 11.16.4. Non-Erosive Gastritis 11.17. Canada Gastritis Treatment Market Forecast, By End user 11.17.1. Government 11.17.2. Hospitals 11.17.3. Medical Practitioners 11.17.4. Others 11.18. North America Gastritis Treatment Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Type 11.18.3. By End user 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Gastritis Treatment Market Analysis 12.1. Key Findings 12.2. Europe Gastritis Treatment Market Overview 12.3. Europe Gastritis Treatment Market Value Share Analysis, By Drug Class 12.4. Europe Gastritis Treatment Market Forecast, By Drug Class 12.4.1. Acid blocking medicines 12.4.2. Antibiotics 12.4.3. Antacids 12.4.4. Acid reducing medicines 12.4.5. Others 12.5. Europe Gastritis Treatment Market Value Share Analysis, By Type 12.6. Europe Gastritis Treatment Market Forecast, By Type 12.6.1.1. Acute Gastritis 12.6.1.2. Chronic Gastritis 12.6.1.3. Erosive Gastritis 12.6.1.4. Non-Erosive Gastritis 12.7. Europe Gastritis Treatment Market Value Share Analysis, By End user 12.8. Europe Gastritis Treatment Market Forecast, By End user 12.8.1. Government 12.8.2. Hospitals 12.8.3. Medical Practitioners 12.8.4. Others 12.9. Europe Gastritis Treatment Market Value Share Analysis, by Country 12.10. Europe Gastritis Treatment Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Gastritis Treatment Market Analysis, by Country 12.12. Germany Gastritis Treatment Market Forecast, By Drug Class 12.12.1. Acid blocking medicines 12.12.2. Antibiotics 12.12.3. Antacids 12.12.4. Acid reducing medicines 12.12.5. Others 12.13. Germany Gastritis Treatment Market Forecast, By Type 12.13.1. Acute Gastritis 12.13.2. Chronic Gastritis 12.13.3. Erosive Gastritis 12.13.4. Non-Erosive Gastritis 12.14. Germany Gastritis Treatment Market Forecast, By End user 12.14.1. Government 12.14.2. Hospitals 12.14.3. Medical Practitioners 12.14.4. Others 12.15. U.K. Gastritis Treatment Market Forecast, By Drug Class 12.15.1. Acid blocking medicines 12.15.2. Antibiotics 12.15.3. Antacids 12.15.4. Acid reducing medicines 12.15.5. Others 12.16. U.K. Gastritis Treatment Market Forecast, By Type 12.16.1. Acute Gastritis 12.16.2. Chronic Gastritis 12.16.3. Erosive Gastritis 12.16.4. Non-Erosive Gastritis 12.17. U.K. Gastritis Treatment Market Forecast, By End user 12.17.1. Government 12.17.2. Hospitals 12.17.3. Medical Practitioners 12.17.4. Others 12.18. France Gastritis Treatment Market Forecast, By Drug Class 12.18.1. Acid blocking medicines 12.18.2. Antibiotics 12.18.3. Antacids 12.18.4. Acid reducing medicines 12.18.5. Others 12.19. France Gastritis Treatment Market Forecast, By Type 12.19.1. Acute Gastritis 12.19.2. Chronic Gastritis 12.19.3. Erosive Gastritis 12.19.4. Non-Erosive Gastritis 12.20. France Gastritis Treatment Market Forecast, By End user 12.20.1. Government 12.20.2. Hospitals 12.20.3. Medical Practitioners 12.20.4. Others 12.21. Italy Gastritis Treatment Market Forecast, By Drug Class 12.21.1. Acid blocking medicines 12.21.2. Antibiotics 12.21.3. Antacids 12.21.4. Acid reducing medicines 12.21.5. Others 12.22. Italy Gastritis Treatment Market Forecast, By Type 12.22.1. Acute Gastritis 12.22.2. Chronic Gastritis 12.22.3. Erosive Gastritis 12.22.4. Non-Erosive Gastritis 12.23. Italy Gastritis Treatment Market Forecast, By End user 12.23.1. Government 12.23.2. Hospitals 12.23.3. Medical Practitioners 12.23.4. Others 12.24. Spain Gastritis Treatment Market Forecast, By Drug Class 12.24.1. Acid blocking medicines 12.24.2. Antibiotics 12.24.3. Antacids 12.24.4. Acid reducing medicines 12.24.5. Others 12.25. Spain Gastritis Treatment Market Forecast, By Type 12.25.1. Acute Gastritis 12.25.2. Chronic Gastritis 12.25.3. Erosive Gastritis 12.25.4. Non-Erosive Gastritis 12.26. Spain Gastritis Treatment Market Forecast, By End user 12.26.1. Government 12.26.2. Hospitals 12.26.3. Medical Practitioners 12.26.4. Others 12.27. Rest of Europe Gastritis Treatment Market Forecast, By Drug Class 12.27.1. Acid blocking medicines 12.27.2. Antibiotics 12.27.3. Antacids 12.27.4. Acid reducing medicines 12.27.5. Others 12.28. Rest of Europe Gastritis Treatment Market Forecast, By Type 12.28.1. Acute Gastritis 12.28.2. Chronic Gastritis 12.28.3. Erosive Gastritis 12.28.4. Non-Erosive Gastritis 12.29. Rest of Europe Gastritis Treatment Market Forecast, By End user 12.29.1. Government 12.29.2. Hospitals 12.29.3. Medical Practitioners 12.29.4. Others 12.30. Europe Gastritis Treatment Market Attractiveness Analysis 12.30.1. By Drug Class 12.30.2. By Type 12.30.3. By End user 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Gastritis Treatment Market Analysis 13.1. Key Findings 13.2. Asia Pacific Gastritis Treatment Market Overview 13.3. Asia Pacific Gastritis Treatment Market Value Share Analysis, By Drug Class 13.4. Asia Pacific Gastritis Treatment Market Forecast, By Drug Class 13.4.1. Acid blocking medicines 13.4.2. Antibiotics 13.4.3. Antacids 13.4.4. Acid reducing medicines 13.4.5. Others 13.5. Asia Pacific Gastritis Treatment Market Value Share Analysis, By Type 13.6. Asia Pacific Gastritis Treatment Market Forecast, By Type 13.6.1.1. Acute Gastritis 13.6.1.2. Chronic Gastritis 13.6.1.3. Erosive Gastritis 13.6.1.4. Non-Erosive Gastritis 13.7. Asia Pacific Gastritis Treatment Market Value Share Analysis, By End user 13.8. Asia Pacific Gastritis Treatment Market Forecast, By End user 13.8.1. Government 13.8.2. Hospitals 13.8.3. Medical Practitioners 13.8.4. Others 13.9. Asia Pacific Gastritis Treatment Market Value Share Analysis, by Country 13.10. Asia Pacific Gastritis Treatment Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Gastritis Treatment Market Analysis, by Country 13.12. China Gastritis Treatment Market Forecast, By Drug Class 13.12.1. Acid blocking medicines 13.12.2. Antibiotics 13.12.3. Antacids 13.12.4. Acid reducing medicines 13.12.5. Others 13.13. China Gastritis Treatment Market Forecast, By Type 13.13.1. Acute Gastritis 13.13.2. Chronic Gastritis 13.13.3. Erosive Gastritis 13.13.4. Non-Erosive Gastritis 13.14. China Gastritis Treatment Market Forecast, By End user 13.14.1. Government 13.14.2. Hospitals 13.14.3. Medical Practitioners 13.14.4. Others 13.15. India Gastritis Treatment Market Forecast, By Drug Class 13.15.1. Acid blocking medicines 13.15.2. Antibiotics 13.15.3. Antacids 13.15.4. Acid reducing medicines 13.15.5. Others 13.16. India Gastritis Treatment Market Forecast, By Type 13.16.1. Acute Gastritis 13.16.2. Chronic Gastritis 13.16.3. Erosive Gastritis 13.16.4. Non-Erosive Gastritis 13.17. India Gastritis Treatment Market Forecast, By End user 13.17.1. Government 13.17.2. Hospitals 13.17.3. Medical Practitioners 13.17.4. Others 13.18. Japan Gastritis Treatment Market Forecast, By Drug Class 13.18.1. Acid blocking medicines 13.18.2. Antibiotics 13.18.3. Antacids 13.18.4. Acid reducing medicines 13.19. Others Japan Gastritis Treatment Market Forecast, By Type 13.19.1. Acute Gastritis 13.19.2. Chronic Gastritis 13.19.3. Erosive Gastritis 13.19.4. Non-Erosive Gastritis 13.20. Japan Gastritis Treatment Market Forecast, By End user 13.20.1. Government 13.20.2. Hospitals 13.20.3. Medical Practitioners 13.20.4. Others 13.21. ASEAN Gastritis Treatment Market Forecast, By Drug Class 13.21.1. Acid blocking medicines 13.21.2. Antibiotics 13.21.3. Antacids 13.21.4. Acid reducing medicines 13.21.5. Others 13.22. ASEAN Gastritis Treatment Market Forecast, By Type 13.22.1. Acute Gastritis 13.22.2. Chronic Gastritis 13.22.3. Erosive Gastritis 13.22.4. Non-Erosive Gastritis 13.23. ASEAN Gastritis Treatment Market Forecast, By End user 13.23.1. Government 13.23.2. Hospitals 13.23.3. Medical Practitioners 13.23.4. Others 13.24. Rest of Asia Pacific Gastritis Treatment Market Forecast, By Drug Class 13.24.1. Acid blocking medicines 13.24.2. Antibiotics 13.24.3. Antacids 13.24.4. Acid reducing medicines 13.24.5. Others 13.25. Rest of Asia Pacific Gastritis Treatment Market Forecast, By Type 13.25.1. Acute Gastritis 13.25.2. Chronic Gastritis 13.25.3. Erosive Gastritis 13.25.4. Non-Erosive Gastritis 13.26. Rest of Asia Pacific Gastritis Treatment Market Forecast, By End user 13.26.1. Government 13.26.2. Hospitals 13.26.3. Medical Practitioners 13.26.4. Others 13.27. Asia Pacific Gastritis Treatment Market Attractiveness Analysis 13.27.1. By Drug Class 13.27.2. By Type 13.27.3. By End user 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Gastritis Treatment Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Gastritis Treatment Market Overview 14.3. Middle East & Africa Gastritis Treatment Market Value Share Analysis, By Drug Class 14.4. Middle East & Africa Gastritis Treatment Market Forecast, By Drug Class 14.4.1. Acid blocking medicines 14.4.2. Antibiotics 14.4.3. Antacids 14.4.4. Acid reducing medicines 14.4.5. Others 14.5. Middle East & Africa Gastritis Treatment Market Value Share Analysis, By Type 14.6. Middle East & Africa Gastritis Treatment Market Forecast, By Type 14.6.1.1. Acute Gastritis 14.6.1.2. Chronic Gastritis 14.6.1.3. Erosive Gastritis 14.6.1.4. Non-Erosive Gastritis 14.7. Middle East & Africa Gastritis Treatment Market Value Share Analysis, By End user 14.8. Middle East & Africa Gastritis Treatment Market Forecast, By End user 14.8.1. Government 14.8.2. Hospitals 14.8.3. Medical Practitioners 14.8.4. Others 14.9. Middle East & Africa Gastritis Treatment Market Value Share Analysis, by Country 14.10. Middle East & Africa Gastritis Treatment Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Gastritis Treatment Market Analysis, by Country 14.12. GCC Gastritis Treatment Market Forecast, By Drug Class 14.12.1. Acid blocking medicines 14.12.2. Antibiotics 14.12.3. Antacids 14.12.4. Acid reducing medicines 14.12.5. Others 14.13. GCC Gastritis Treatment Market Forecast, By Type 14.13.1. Acute Gastritis 14.13.2. Chronic Gastritis 14.13.3. Erosive Gastritis 14.13.4. Non-Erosive Gastritis 14.14. GCC Gastritis Treatment Market Forecast, By End user 14.14.1. Government 14.14.2. Hospitals 14.14.3. Medical Practitioners 14.14.4. Others 14.15. South Africa Gastritis Treatment Market Forecast, By Drug Class 14.15.1. Acid blocking medicines 14.15.2. Antibiotics 14.15.3. Antacids 14.15.4. Acid reducing medicines 14.15.5. Others 14.16. South Africa Gastritis Treatment Market Forecast, By Type 14.16.1. Acute Gastritis 14.16.2. Chronic Gastritis 14.16.3. Erosive Gastritis 14.16.4. Non-Erosive Gastritis 14.17. South Africa Gastritis Treatment Market Forecast, By End user 14.17.1. Government 14.17.2. Hospitals 14.17.3. Medical Practitioners 14.17.4. Others 14.18. Rest of Middle East & Africa Gastritis Treatment Market Forecast, By Drug Class 14.18.1. Acid blocking medicines 14.18.2. Antibiotics 14.18.3. Antacids 14.18.4. Acid reducing medicines 14.18.5. Others 14.19. Rest of Middle East & Africa Gastritis Treatment Market Forecast, By Type 14.19.1. Acute Gastritis 14.19.2. Chronic Gastritis 14.19.3. Erosive Gastritis 14.19.4. Non-Erosive Gastritis 14.20. Middle East & Africa Gastritis Treatment Market Forecast, By End user 14.20.1. Government 14.20.2. Hospitals 14.20.3. Medical Practitioners 14.20.4. Others 14.21. Middle East & Africa Gastritis Treatment Market Attractiveness Analysis 14.21.1. By Drug Class 14.21.2. By Type 14.21.3. By End user 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Gastritis Treatment Market Analysis 15.1. Key Findings 15.2. South America Gastritis Treatment Market Overview 15.3. South America Gastritis Treatment Market Value Share Analysis, By Drug Class 15.4. South America Gastritis Treatment Market Forecast, By Drug Class 15.4.1. Acid blocking medicines 15.4.2. Antibiotics 15.4.3. Antacids 15.4.4. Acid reducing medicines 15.4.5. Others 15.5. South America Gastritis Treatment Market Value Share Analysis, By Type 15.6. South America Gastritis Treatment Market Forecast, By Type 15.6.1.1. Acute Gastritis 15.6.1.2. Chronic Gastritis 15.6.1.3. Erosive Gastritis 15.6.1.4. Non-Erosive Gastritis 15.7. South America Gastritis Treatment Market Value Share Analysis, By End user 15.8. South America Gastritis Treatment Market Forecast, By End user 15.8.1. Government 15.8.2. Hospitals 15.8.3. Medical Practitioners 15.8.4. Others 15.9. South America Gastritis Treatment Market Value Share Analysis, by Country 15.10. South America Gastritis Treatment Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Gastritis Treatment Market Analysis, by Country 15.12. Brazil Gastritis Treatment Market Forecast, By Drug Class 15.12.1. Acid blocking medicines 15.12.2. Antibiotics 15.12.3. Antacids 15.12.4. Acid reducing medicines 15.12.5. Others 15.13. Brazil Gastritis Treatment Market Forecast, By Type 15.13.1. Acute Gastritis 15.13.2. Chronic Gastritis 15.13.3. Erosive Gastritis 15.13.4. Non-Erosive Gastritis 15.14. Brazil Gastritis Treatment Market Forecast, By End user 15.14.1. Oil & Gas 15.14.2. Government 15.14.3. Hospitals 15.14.4. Medical Practitioners 15.14.5. Others 15.15. Mexico Gastritis Treatment Market Forecast, By Drug Class 15.15.1. Acid blocking medicines 15.15.2. Antibiotics 15.15.3. Antacids 15.15.4. Acid reducing medicines 15.15.5. Others 15.16. Mexico Gastritis Treatment Market Forecast, By Type 15.16.1. Acute Gastritis 15.16.2. Chronic Gastritis 15.16.3. Erosive Gastritis 15.16.4. Non-Erosive Gastritis 15.17. Mexico Gastritis Treatment Market Forecast, By End user 15.17.1. Government 15.17.2. Hospitals 15.17.3. Medical Practitioners 15.17.4. Others 15.18. Rest of South America Gastritis Treatment Market Forecast, By Drug Class 15.18.1. Acid blocking medicines 15.18.2. Antibiotics 15.18.3. Antacids 15.18.4. Acid reducing medicines 15.18.5. Others 15.19. Rest of South America Gastritis Treatment Market Forecast, By Type 15.19.1. Acute Gastritis 15.19.2. Chronic Gastritis 15.19.3. Erosive Gastritis 15.19.4. Non-Erosive Gastritis 15.20. Rest of South America Gastritis Treatment Market Forecast, By End user 15.20.1. Government 15.20.2. Hospitals 15.20.3. Medical Practitioners 15.20.4. Others 15.21. South America Gastritis Treatment Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Type 15.21.3. By End user 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward 16.2.3.3. Integration 16.3. Company Profiles: Key Players 16.3.1. Pfizer 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. AstraZeneca 16.3.3. Novartis 16.3.4. Cipla 16.3.5. Teva Pharmaceuticals 16.3.6. Abbott Laboratories 16.3.7. Microbiotix 16.3.8. Reddy's Laboratories 16.3.9. Lupin Ltd 16.3.10. Perrigo Pharmaceutical 16.3.11. Zydus Cadila Healthcare Limited 16.3.12. Sun Pharmaceutical Industries 16.3.13. PT Otsuka Indonesia

About This Report

Report ID 70131
Category Electronics
Published Date Auguet2020
Updated Date
Contact Us